Blake Wise Email Address

Chief Executive Officer

Achaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). Plazomicin is an aminoglycoside designed to overcome clinically relevant aminoglycoside resistance mechanisms. In addition, its research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections: a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program. Its development plan for plazomicin includes over two Phase III clinical trials.

Executive with 20 years of commercial leadership experience, with strategic and operational roles of increasing scale in the biotech and pharmaceutical industry, along with prior startup experience in technology and online retail. Blake has a consistent track record of developing new capabilities, delivering product and portfolio performance and building high-performing teams across specialty markets, such as oncology, immunology, acute care and respiratory disease. Specialties: Executive leadership, commercialization, early commercialization, new product launches, commercial and corporate strategy, new ventures, life cycle management, managed markets, pricing, reimbursement, account management, sales, marketing, branding, positioning, digital health, companion diagnostics, big data applications, competitive strategy, web marketing, retail, product management.